Aliases:This biomarker is also known as:
- mitochondrial ribonuclease P protein 2,
- mental retardation, X-linked, syndromic 10,
- short chain L-3-hydroxyacyl-CoA dehydrogenase type 2,
- 3-hydroxyacyl-CoA dehydrogenase type-2,
- AB-binding alcohol dehydrogenase,
- hydroxysteroid (17-beta) dehydrogenase 10,
- Endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- 3-hydroxy-2-methylbutyryl-CoA dehydrogenase,
- Mitochondrial RNase P protein 2,
- 17-beta-hydroxysteroid dehydrogenase 10,
- endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- Short-chain type dehydrogenase/reductase XH98G2,
- Type II HADH,
- short chain dehydrogenase/reductase family 5C, member 1,
- 17-beta-HSD 10,
- 3-hydroxyacyl-CoA dehydrogenase type II,
- mitochondrial RNase P subunit 2,
- short chain type dehydrogenase/reductase XH98G2,
- Mitochondrial ribonuclease P protein 2,
- amyloid-beta peptide binding alcohol dehydrogenase,
- EC 22.214.171.124,EC 126.96.36.199,
- hydroxyacyl-Coenzyme A dehydrogenase, type II, hydroxyacyl-Coenzyme A dehydrogenase, type II,
HSD17B10, hydroxysteroid (17-beta) dehydrogenase 10, is a member of the short-chain dehydrogenase/reductase superfamily. HSD17B10 functions in mitochondrial tRNA maturation and catalyzes the oxidation of a wide variety of fatty acids, alcohols, and steroids. The protein is thought to play a role in the development of Alzheimer's disease. There are several alternatively spliced transcript variants, of which only two have been fully sequenced.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data is available.
HSD17B10 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
|UniProt Accession #:||Q99714|
|Mutated Sites Count:||28|
|Associated Pubmed ID Count||0|
|Affected Protein Function Sites Count:||3|